This publication provides postmarketing information to healthcare professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting.
List of drug safety advisories posted on FDA’s Web site from September 1, 2008 through November 30, 2008, with related links
U.S. Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
5600 Fishers Lane, Rockville MD 20857-0001
Phone: 1-888-INFO-FDA (1-888-463-6332)
Office of Surveillance and Epidemiology and Office of New Drugs
Renan A. Bonnel, PharmD, MPH
Senior Scientific Editor
Gregory D. Busse, PhD
Martin Pollock, PharmD, Joann H. Lee, PharmD (varenicline and bupropion)
Ida-Lina Diak, PharmD, John Senior, MD (atomoxetine)
Wendy Carter, MD, Kendall Marcus, MD (abacavir)
Art Direction and Design: Elena H. Ketelhut
We value your comments. Please let us know by reaching us at www.fda.gov/cder/comment.htm. All text in the Drug Safety Newsletter is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.